跳至主要内容
临床试验/NCT03167060
NCT03167060已完成不适用

Nasal Cavity Cooling for the Symptomatic Relief of Migraine Headache - A Randomized, Double Blind, Placebo Controlled Study" , the BrainCool-Migraine Study

Cumbria Partnership NHS Foundation Trust5 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2017年5月8日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
90
试验地点
5
主要终点
Participant is pain free at two hours following trial device treatment The patients' first treatment will be used for analysis of the superiority of the rate of patients pain free at two hours following treatment for those receiving the standard R

研究概览

简要总结

This study will be a randomised placebo controlled trial examining the effectiveness of using an intranasal evaporative cooling device (the RhinoChill intransal device) in providing relief of pain and symptoms of acute migraine.The treatment works by introducing cooling into the passageways of the nose through two small cannulas thereby cooling the local nasal tissue and the blood vessels which supply blood to the brain. This cooling effect will cause the blood vessels to constrict as well as stimulating special cold receptors that are thought to be involved in the relief of migraine, thereby providing both pain and associated symptomatic relief. In total, 90 patients randomised in a 1:1 fashio n will be recruited from three different NHS Trusts. The patients will have a 30-day period of data collection for their current migraine frequency, treatment and response to medication (with a minimum of 2 migraine attacks recorded) before starting the treatment phase with the RhinoChill Device. Treatment will be for 3 migraine attacks. Only a single treatment is allowed for the first attack, but on the second attack the patient may deliver 2 treatments with a gap of at least 2 hours between treatments, if indicated.

详细描述

Mechanical techniques to alleviate migraine symptoms have been used for many years, cooling and compression being the most frequently applied. Cryotherapy is the most common non-pharmacological self-administered pain-relieving method currently used by migraine sufferers. The first manuscript documenting the application of ice mixtures was published by James Arnott in 1849. Simple techniques based on cryotherapy, using various methods of cold and ice application have been reported over the last three decades. Friedman described a device using hollow metal tubes cooled by circulating cold water, applied to the periapical area of the maxillary molars. Sprouse-Blum reported benefit from applying frozen icepacks targeting carotid arteries at the front of the neck in migraine treatment.

Several pathophysiological mechanisms of action have been proposed. These mechanisms include:

  1. Neurovascular mechanism: Application of cold induces vasoconstriction with subsequent decreased downstream blood flow. This leads to inhibition of the release of inflammatory mediators which results in decreased vascular permeability and local oedema.
  2. Pain gating by differential effect on nerve conduction: Cryotherapy induces analgesia by slowing nerve conduction velocity, with small myelinated fibers being affected first, followed by large myelinated fibers and the unmyelinated fibers being affected last. Via mechanism of the gate control of pain, affecting the small myelinated nociceptive pain afferents first, cryotherapy induces analgesia.
  3. Metabolic mechanism: Cryotherapy decreases metabolic and enzymatic activity, due to reduced demand for adenosine triphosphate (ATP) and oxygen.
  4. Transient Receptor Potential (TRP) channels: Recent studies suggest that TRP channels may have a role in headache and pain genesis due to their response to environmental stimuli such as temperature changes.

The nasal cavity provides a large diffuse surface area that is highly vascular. Cooling via the nasal cavity therefore offers the ability to cool across the thin cribriform plate via both direct conductive mechanisms that do not rely on spontaneous circulation as well as indirect haematogenous mechanisms. Numerous subarachnoid and pial arterial branches exposed to the cerebrospinal fluid (CSF) have diameters in the range of the vessels of the retia mirabilia of animals in which selective brain cooling has been clearly established experimentally. Vascular anatomy allows transfer of venous blood from the skin of the head as well as nasal and paranasal mucous membranes to the dura mater thereby providing an excellent basis for the convective process of intranasal evaporative cooling. The dura mater, with its high vascularization, may transmit temperature changes to the CSF compartment, which may influence the temperature of brain parenchyma directly or indirectly, via brain arteries.

We suppose that another effect of intranasal cooling may be local vasoconstriction and subsequent associated vasoconstriction of cerebral arteries due to the presence of the nebulized coolant in the nasal cavity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Controls will undergo same treatment with the medical device, but it will be a sham treatment

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 Years old or over and ≤70 years of age.
  • Migraine diagnosis of at least 1 year
  • Migraine attacks between 1 and 15 per month
  • Onset of first migraine < 50 years of age
  • Migraine prophylaxis medication unchanged for 3 months prior to enrollment
  • Meets International Classification for Headache Disorders (2nd Edition) criteria for diagnosis of Episodic Migraine with or without aura
  • Able to attend a short training session on the practical use of the RhinoChill® device and agrees to only use the device as instructed and as laid out in the official instructions for use

排除标准

  • < 18 and >70 years of age
  • Known oxygen dependency to maintain SaO2 >95%
  • Diagnosed Hypertensive and currently uncontrolled with Systolic BP > 140mmHg and Diastolic BP > 90mmHg on baseline assessment.
  • Marked nasal septal deviation, recurrent epistaxis or chronic Rhino-Sinusitis.
  • Intranasal obstruction preventing full insertion of nasal catheter.
  • Known base of skull fracture or facial trauma
  • Concurrent sinus/intranasal surgery
  • Diagnosed with Thromobocytopenia
  • Previous Stroke or Myocardial Infarction
  • Unable to fully understand the consent process and provide informed consent due to either language barriers or mental capacity
  • Previously enrolled into the COOLHEAD 1 trial.
  • No recorded migraine following initial 30 day data collection period

研究组 & 干预措施

Active Rhinochill

Active Comparator

Intranasal cooling device , using nasal cannula

干预措施: Active RhinoChill (Device)

Control Rhinochill

Sham Comparator

Intranasal cooling device , using nasal cannula (difference with active device not disclosed to maintain blindness)

干预措施: Control Rhinochill (Device)

结局指标

主要结局

Participant is pain free at two hours following trial device treatment The patients' first treatment will be used for analysis of the superiority of the rate of patients pain free at two hours following treatment for those receiving the standard R

时间窗: two hours

The first treatment with the RhinoChill device will be used for analysis of the superiority of the rate of participants who are pain free at two hours following treatment for those receiving the standard RhinoChill® treatment. This will be compared to those participants who are randomised to receive sham device treatment. Likert scale questionnaire will record the outcome

次要结局

  • Percentage of patients pain free immediately after treatment (10 minutes), at 1 hour, and 24 hours following treatment(10 minutes, 1 hour, 24 hours)
  • Headache response(10 min, 1 hour, 2 hours, 24 hours)
  • relapse incidence(2 hours, 48 hours)
  • Sustained pain freedom(2 hours, 48 hours)
  • Total migraine freedom(2 hours)

研究者

发起方
Cumbria Partnership NHS Foundation Trust
申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验